Loading clinical trials...
Loading clinical trials...
A Phase II, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Conditions
Interventions
huMAb OX40L
placebo
Start Date
September 1, 2009
Primary Completion Date
August 1, 2010
Completion Date
January 1, 2011
Last Updated
August 2, 2016
NCT02327897
NCT07486401
NCT07219173
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions